Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Gao, Jin Hang ^a   Wen, Shi Lei ^a   Yang, Wen Juan ^a   Lu, Yao Yao ^a   Tong, Huan ^a   Huang, Zhi Yin ^a   Liu, Zhang Xu ^b   Tang, Cheng Wei ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; CELECOXIB; COLLAGEN TYPE 3; CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; PROTEIN C FOS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE CONTROL; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RAT; SIGNAL TRANSDUCTION; UPREGULATION; VEIN CATHETERIZATION; VENULE;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; HYPERTENSION, PORTAL; KIDNEY; LIVER CIRRHOSIS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SULFONAMIDES; THIOACETAMIDE;

EID: 84880801589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069309     Document Type: Article

References (33)

1. Bosch J, Garcia-Pagan JC, (2000) Complications of cirrhosis. I. Portal hypertension. J Hepatol 32: 141-156.
2. Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC, (2010) Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53: 558-567.
3. Thabut D, Shah V, (2010) Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 53: 976-980.
4. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, et al. (2008) Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 135: 1729-1738.
5. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, et al. (2002) Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35: 1010-1021.
6. Masyuk TV, Ritman EL, LaRusso NF, (2003) Hepatic artery and portal vein remodeling in rat liver: vascular response to selective cholangiocyte proliferation. Am J Pathol 162: 1175-1182.
7. Jain RK, Carmeliet P (2012) SnapShot: Tumor angiogenesis. Cell 149: 1408-1408 e1401.
8. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, et al. (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46: 1919-1926.
9. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, et al. (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54: 573-585.
10. Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, et al. (2011) Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 53: 1629-1640.
11. Carmeliet P, Jain RK, (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
12. Samant RS, Shevde LA, (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2: 122-134.
13. Verheul HM, Pinedo HM, (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475-485.
14. Chen HX, Cleck JN, (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477.
15. Smith WL, DeWitt DL, Garavito RM, (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182.
16. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, et al. (2009) Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci 1155: 293-299.
17. Sahin M, Sahin E, Gumuslu S, (2009) Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60: 242-253.
18. Xie Y, Chen S, Wang CH, Tang CW, (2011) SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. Cancer Biol Ther 12: 86-92.
19. Tong H, Li X, Zhang CL, Gao JH, Wen SL, et al. (2013) Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. J Dig Dis 14: 29-37.
20. Wang R, Guo L, Wang P, Yang W, Lu Y, et al. (2013) Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des 19: 115-125.
21. Friedman SL, (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
22. Fallowfield JA, (2011) Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300: G709-715.
23. Rockey DC (2008) Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12: 939-962, xi.
24. Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, et al. (2009) Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 58: 1517-1527.
25. Lee JS, Semela D, Iredale J, Shah VH, (2007) Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 45: 817-825.
26. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49: 1245-1256.
27. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, et al. (2009) Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50: 1501-1511.
28. Xiao Z, Kong Y, Yang S, Li M, Wen J, et al. (2007) Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. Cell Res 17: 73-79.
29. Hui AY, Leung WK, Chan HL, Chan FK, Go MY, et al. (2006) Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 26: 125-136.
30. Yu J, Hui AY, Chu ES, Go MY, Cheung KF, et al. (2009) The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. Liver Int 29: 25-36.
31. Liu H, Wei W, Li X, (2009) Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. Prostaglandins Other Lipid Mediat 88: 63-67.
32. McCormack PL, (2011) Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71: 2457-2489.
33. Maddrey WC, Maurath CJ, Verburg KM, Geis GS, (2000) The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 7: 153-158.